Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

EMD Millipore and PharmaCell Announces Collaboration

Published: Friday, May 24, 2013
Last Updated: Friday, May 24, 2013
Bookmark and Share
Collaboration to evaluate EMD Millipore’s Mobius® bioreactor platform for expansion of HepaRG® cells.

EMD Millipore and PharmaCell B.V. have announced a collaboration to develop optimized large-scale expansion and harvest of HepaRG® cells using bioreactor technology.

The companies will work together to produce protocols and methods for efficient expansion, harvest and use of HepaRG® cells in support of the BALANCE project, which is funded by the Seventh Framework Programme of the European Committee and aims to create bioartificial livers.

Large-scale methods to produce cells have typically been manufactured in multi-layer flasks. Bioreactors provide a method that can meet the needs of large-scale production for safe and effective delivery of cell-based therapies.

Ultimately the project is expected to deliver scalable expansion and harvesting devices, validation methods and associated protocols for the production of large-scale stem cell therapies.

Large-scale “industrialized” production of cells is necessary to enable their advancement into human clinical trials and to effectively deliver the quantities efficiently and effectively.

However, achieving this level of production while meeting rigorous quality standards will depend on further progress in the areas of cell culture and scale-up, characterization, enrichment and purification to deliver a consistent and reproducible supply of cells.

“As more cell-based therapeutics progress towards clinical testing, the consistency, quality and reproducibility of large-scale culture systems become an imperative,” notes Robert Shaw, Commercial Director of EMD Millipore’s Stem Cell Initiative.

Shaw continued, “The ability to ensure that a population of cells can be reproducibly produced in a manner that can be validated is critical to the success of clinical applications. The technologies developed as part of this collaboration will help enable this and move the field forward.”

“We are excited to work with EMD Millipore to develop the future technologies for large-scale industrial production of human cells. EMD Millipore’s world-class technical expertise in bioreactors combined with PharmaCell’s advanced know-how in culturing human cells positions the team well to create solutions to overcome some significant technical hurdles in the field and lower future cost of goods sold for our clients,” expresses Alexander Vos, Chief Executive Officer, PharmaCell BV.

This collaboration is another step in the development of a platform of scalable, disposable production solutions to help enable manufacturers of cell-based therapies.

PharmaCell provides GMP contract manufacturing services and process development solutions in the area of cell therapy and regenerative medicine. They will be utilizing the Mobius® bioreactor platform in support of this project.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Vaccine Against Common Cold Achievable
Researchers suggest that a vaccine against rhinoviruses is possible using variant virus vaccines.
New Weapon Against Hard-to-Treat Bacterial Infections
Using peptides, researchers have been able to prevent drug-resistance bacteria from forming abscesses.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!